SOMAVAC®  Named One of “Five Companies to Watch” from LSI Market Insights

At the core of LSI’s Emerging Medtech Summits are our innovators. This year, 362 early and growth-stage companies took the stage to share how their technologies aim to improve outcomes and extend lives.

With so many impressive presentations, our Market Intelligence analyst team selected five standout companies to highlight, each bringing differentiated technology, validated market demand, and momentum.

Let’s take a look at The Numbers.

The Somavac system is designed to apply deep tissue Negative Pressure Therapy to reduce and prevent the occurrence of seroma in patients who have recently undergone breast reconstruction and mastectomies.

Somavac’s system is intended to reduce post-operative complications and the time requiring surgical drains following surgery. The system is self-contained within a belt to discretely remove fluid and prevent build-up that can lead to complications.

Market Insights

In 2024 an estimated 1.2 million breast reconstruction and mastectomies were performed worldwide. These procedures are projected to see moderate growth over the next five years, increasing at a CAGR of 2.3%.

Risk of complications is clinically relevant among breast cancer surgery. Depending on the extensiveness of the surgery, post-operative risk of complications, of which seroma is common, ranges from 3% to 15%.

CEO Elizabeth Hoff presenting at LSI in Dana Point, CA

Read the whole article here: https://www.linkedin.com/pulse/analyst-perspective-five-companies-watch-from-w18ke/